Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases
Cancer · 2025-08 · 131 (15)
DOI: 10.1002/cncr.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 22.07.2025. Verfasst von Chun Qiao und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: RNA Splicing Factors, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Natural Science Foundation, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Splicing factor 3b subunit 1 ( SF3B1 ) mutations have been implicated in hematologic malignancies, but the clinical significance of distinct SF3B1 mutation variants remain unclear.
Methods
The objective of this study was to evaluate clinicopathologic features, mutational profiles, and outcomes of 1691 patients with hematologic malignancies, including myelodysplastic syndromes (MDS; n = 402), acute myeloid leukemia (AML; n = 758), and chronic lymphocytic leukemia (CLL; n = 531).
Results
The frequency of SF3B1 ‐mutated ( SF3B1 MUT ) MDS, AML, and CLL was 70 of 402 patients (17.4%), 23 of 758 patients (3.0%), and 45 of 531 patients (8.5%), respectively. p.K700E was the most prevalent SF3B1 MUT variant and was identified in 43 of 70 of patients with MDS (61.4%), in seven of 23 patients with AML (30.4%), and in 19 of 45 patients with CLL (42.2%). In MDS and AML, TET2 was the most frequent co‐mutated gene in patients with SF3B1 MUT disease (20 of 70 patients with MDS [28.6%]; 11 of 23 patients with AML [47.8%]). For patients with SF3B1 MUT CLL, the most common co‐mutated genes were ATM (11 of 45; 24.4%) and TP53 (11 of 45; 24.4%). Kaplan–Meier analysis indicated that the SF3B1 p.K700E variant was significantly associated with improved overall survival (OS) and progression‐free survival (PFS) in patients who had MDS ( p < .001 and p = .016, respectively) but with worse OS and PFS in those who had AML ( p = .006 and p = .006, respectively) compared with those who had wild‐type SF3B1 . In patients who had CLL, p.I704F was associated with reduced OS ( p < .001) and p.K700E was associated with a shorter time‐to‐first treatment ( p = .028) compared with those who had wild‐type SF3B1 . Multivariable analysis identified p.K700E as an independent protective factor for OS in patients with MDS ( p = .048) but as an independent risk factor for both OS and PFS in patients with AML ( p = .036 and p = .035, respectively) and for the time to first treatment in patients with CLL ( p = .033).
Conclusions
Specific SF3B1 variants should be incorporated into prognostic stratification for hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
- Department of Hematology, Lymphoma Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
ORCID-Profile: Sixuan Qian, Yi Miao, Huimin Jin
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Natural Science Foundation
- China Postdoctoral Science Foundation
- Jiangsu Postdoctoral Science Foundation of China
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
- Jiangsu Province Hospital High-Level Talent Cultivation Program, Phase I
Zitieren
APA
Qiao, C., Xia, Y., Guo, Z., Zhu, L., Wu, Y., Qiu, H., Wang, Y., Zhu, H., Qian, S., Hong, M., Zhu, Y., Shen, W., Gong, Y., Jin, H., Fan, L., Li, J., Yang, Y., He, G., Miao, Y., & Jin, H. (2025). Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases. Cancer, 131(15). https://doi.org/10.1002/cncr.70017
Vancouver
Qiao C, Xia Y, Guo Z, Zhu L, Wu Y, Qiu H, et al. Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases. Cancer. 2025;131(15). doi:10.1002/cncr.70017
BibTeX
@article{Qiao2025,
author = {Qiao, Chun and Xia, Yi and Guo, Zhen and Zhu, Liying and Wu, Yujie and Qiu, Hairong and Wang, Yan and Zhu, Huayuan and Qian, Sixuan and Hong, Ming and Zhu, Yu and Shen, Wenyi and Gong, Yuemin and Jin, Hui and Fan, Lei and Li, Jianyong and Yang, Yong and He, Guangsheng and Miao, Yi and Jin, Huimin},
title = {Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases},
journal = {Cancer},
year = {2025},
volume = {131},
number = {15},
doi = {10.1002/cncr.70017}
}
EUVIMED